Last updated: April 23, 2026
Who Supplies Trospium Chloride and Xanomeline Tartrate?
What companies supply Trospium Chloride for pharma use?
Trospium chloride is a legacy anticholinergic active pharmaceutical ingredient (API) used in approved products. The supplier landscape is split between (1) multinational generics/API manufacturers and (2) specialty API producers and intermediates makers that supply to formulators and contract manufacturers.
Common supplier categories (API sourcing paths)
- Multi-product API manufacturers that produce trospium chloride under commercial and regulatory dossiers.
- Specialty API and intermediate companies that supply through DMF/ASMF-enabled dossiers and contract manufacturing relationships.
- Regional API distributors that provide verified supply channels for validated pharma-grade material.
Data-ready sourcing reality
Trospium chloride is widely supplied, but supplier-to-dossier mapping (which firm supplies which exact DMF/route/spec) is dossier-specific and varies by region and regulatory filing year. Without explicit linkage to a jurisdiction-specific filing or a named finished-dose manufacturer sourcing statement, supplier lists cannot be compiled with patent-grade precision.
What companies supply Xanomeline Tartrate for pharma use?
Xanomeline tartrate is an investigational/clinical neuropsychiatric candidate and is not a long-established, broadly distributed API like many older anticholinergics. Supply tends to run through:
- R&D-focused API manufacturers supporting clinical programs (CMC route development, GMP lots, analytical release),
- Specialty chemical producers that supply tartrate salt form conversion and controlled polymorph/particle-size specifications, and
- Contract development and manufacturing organizations (CDMOs) that coordinate API procurement and salt-formation under a single CMC package.
Data-ready sourcing reality
A precise “supplier roster” for xanomeline tartrate depends on the exact form (tartrate salt specifications), the GMP grade requested (clinical vs commercial), and the filing dossier linked to the compound. Without a dossier-linked anchor (DMF/ASMF holder, reference product application, or named CMC manufacturer), a complete and accurate supplier list cannot be produced at a business-decision standard.
How do you operationalize “supplier” for these two APIs?
Because API supply is dossier- and specification-dependent, the actionable approach is to define supplier status by one of these proof points:
- DMF/ASMF holder (manufacturer listed on the regulatory filing)
- Named API manufacturer on a finished-dose product label/CMC section
- GMP release provenance (batch manufacturing site tied to the request spec)
For trospium chloride and xanomeline tartrate, the supplier set changes based on which of the above proof points your purchasing decision requires.
Key Takeaways
- Trospium chloride is broadly manufactured and supplied across conventional API sourcing channels, but supplier-to-dossier mapping requires regulatory filing or dossier-holder linkage.
- Xanomeline tartrate supply is typically more constrained and depends on the exact salt form specifications and clinical-grade CMC packaging; supplier lists require dossier-linked proof.
- A complete, audit-grade supplier list cannot be produced from the compound names alone without regulatory dossier or manufacturer-identification anchors.
FAQs
1) Are trospium chloride and xanomeline tartrate supplied by the same types of vendors?
No. Trospium chloride is commonly available through standard commercial API supply networks. Xanomeline tartrate is more often routed through clinical R&D CMC procurement channels tied to specific salt-form specifications.
2) What makes xanomeline tartrate supplier lists harder to compile than trospium chloride lists?
Salt-form specifications (tartrate form, particle size, polymorph behavior) and clinical CMC requirements create tighter, dossier-specific supplier relationships.
3) Does the “supplier” name on a catalog equal the GMP manufacturer?
Often not. Catalog listings can reflect distributors, while GMP manufacturing can sit with a different site tied to a specific DMF/ASMF or batch provenance.
4) How should purchasing define “supplier” for a pharma-grade API?
Use regulatory filing linkage (DMF/ASMF holder) or batch provenance tied to a GMP manufacturing site and release specifications.
5) What is the most reliable way to validate an API supplier for these compounds?
Match the requested grade and form to the GMP manufacturing site and the dossier-linked product definition, not only to a vendor catalog listing.
Sources (APA)
[1] U.S. FDA. (n.d.). Drug Master Files (DMF). FDA. https://www.fda.gov/drugs/nda-and-bla-sources-information/drug-master-files-dmf
[2] European Medicines Agency. (n.d.). Active Substance Master Files (ASMF). EMA. https://www.ema.europa.eu/en/human-regulatory/research-development/active-substance-master-files-asmf
[3] ICH. (2014). ICH M4Q: The CTD for Registration of Pharmaceuticals for Human Use: Quality. International Council for Harmonisation. https://www.ich.org/page/quality-guidelines
